To improve Europe-wide awareness, understanding, and access to diagnosis and treatment of inherited lipid conditions, (specifically FH, HoFH, Lp(a), FCS), so that all those impacted receive optimal treatment and support, resulting in longer and healthier lives.
To achieve early recognition of life-threatening dyslipidaemias for all impacted people, in a future where:
- There is an increased focus on prevention and early detection
- Care is more personalized
- Digital healthcare and online communication have become common
- Patients are relied on to provide expertise, support, and consultation to drive innovation
FH Europe, together with patient organisations and stakeholders will be able to prevent the consequences, including heart attacks and deaths, of inherited dyslipidaemias.
FH Europe is supported by an educational grant from Amgen Limited, Sanofi, Regeneron, Akcea Therapeutics Inc. and Amryt